title: Pharmacogenomics and pharmacologic class effect in drug safety management.
abstract: The safety of FDA-approved drugs remains a significant concern for patients and medical practitioners. This paper argues that pharmacogenomics can complement pharmacologic class effects in drug-safety management, and their use can be implemented without excessive costs or other impracticalities. Section I of this paper introduces key data, concepts and terms; Section II discusses the phenomenon of pharmacologic class effect as well as the relationship between this phenomenon and the use of pharmacogenomics in both FDA regulation and medical practice; and Section III proposes a means by which simultaneous consideration of pharmacologic class effect and pharmacogenomics can improve the quality of selective risk management.
authors: Mikyung
authors: M
authors: Kim
mesh_terms: D004346:Drug Information Services; D064420:Drug-Related Side Effects and Adverse Reactions; D033161:Government Regulation; D007880:Legislation, Drug; D004364:Pharmaceutical Preparations; D010597:Pharmacogenetics; D011358:Product Surveillance, Postmarketing; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D004364:Pharmaceutical Preparations